The substitution, in one paragraph
Through 2024, the default growth-hormone-axis recommendation in regenerative-medicine practice was an Ipamorelin / CJC-1295 (no DAC) pulsatile stack. In May 2026, Limitless retired that recommendation. CJC-1295 is not on the July 2026 PCAC docket and is not currently legal for human compounding under 503A. We rebuilt the GH-axis recommendation around tesamorelin (FDA-approved GHRH analog) as the lead, sermorelin as the alternative where tesamorelin is not indicated or accessible, and ipamorelin as a conditional addition contingent on the partner 503A pharmacy formulary. This article is the evidence anchor for that substitution.
What tesamorelin is
Tesamorelin is a 44-amino-acid GHRH analog. It binds the same pituitary GHRH receptor as endogenous hypothalamic GHRH and stimulates the somatotroph cell to release growth hormone in a pulsatile pattern. Because it acts upstream of the pituitary, the negative-feedback loops that prevent supraphysiologic GH excess — IGF-1 feedback, somatostatin tone — remain intact. This is the structural reason GHRH analogs do not produce the side-effect profile of exogenous HGH administration.
It is approved by the FDA for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy. That approval matters not because most Limitless patients have HIV, but because it is the only peptide on our menu that has cleared the full Phase III development pathway. The trial dossier behind that approval is what we lean on.
The evidence chain, in five layers
Layer 1 — Visceral adipose tissue reduction
The headline tesamorelin effect is a roughly 15–18% reduction in visceral adipose tissue (VAT) over 26 weeks at standard 2 mg daily SubQ dosing. A 2026 five-trial pooled meta-analysis converged on a mean −27.7 cm² VAT reduction with corresponding waist-circumference decline. The effect is consistent across HIV and non-HIV populations and holds up on modern integrase-inhibitor regimens. We covered this in detail in our tesamorelin meta-analysis brief.
Layer 2 — Skeletal muscle area and density
The 2019 Stanley et al. analysis (cited in PMC6766405) reported that among patients with a clinically significant decrease in visceral adipose tissue on tesamorelin, skeletal muscle cross-sectional area and muscle density both increased. This finding matters for a longevity-medicine practice: muscle area predicts sarcopenia trajectory, and muscle density (an MRI-derived measure of intramuscular fat infiltration) is a stronger predictor of functional decline in aging cohorts than scale weight or BMI. A GH-axis intervention that simultaneously decreases visceral fat and increases muscle quality is doing exactly what the body-composition arm of a longevity protocol is supposed to do.
Layer 3 — The exercise-adjunct trial
NCT06554717 (currently recruiting in 2026) is examining tesamorelin as an adjunct to structured exercise in adults with abdominal obesity. The trial design is a 24-week randomized, double-blind, placebo-controlled study with VAT and muscle endpoints, layered on top of a supervised exercise program. The reason this matters now, even before readout, is that it is the first major trial to position tesamorelin in the framework most Limitless patients actually live in: someone who already trains, already eats well, and wants a pharmacologic adjunct that compounds the work they are doing rather than substituting for it. We will update this article when the trial reports.
Layer 4 — The emerging cognitive endpoint
A separate body of work has examined tesamorelin's effect on cognition in mild cognitive impairment and HIV-associated neurocognitive disorder. The signal is small, the trials are small, and the mechanism (GH/IGF-1 axis modulation of hippocampal function) is plausible but not yet load-bearing. We do not prescribe tesamorelin for cognitive indications. We mention the signal because it places tesamorelin in a small group of compounds that have moved past "fat-loss drug" framing in the published literature.
Layer 5 — A clean safety record
Across the Phase II/III dossier and the post-marketing experience, tesamorelin has not produced an IGF-1 excess signal at standard dosing, has not produced an insulin-resistance signal in non-HIV populations, and has not produced a malignancy signal in the time-frames the trials cover. Injection-site reactions are the most common adverse event. We monitor IGF-1 at baseline and every 12 weeks; we titrate or pause if IGF-1 exceeds the age-adjusted upper reference range.
Where sermorelin sits
Sermorelin is a 29-amino-acid GHRH analog — the shortest GHRH fragment that retains receptor binding. It has decades of clinical use, a benign safety record, and a shorter pharmacokinetic profile than tesamorelin. The trial literature is older and smaller, and there is no Phase III equivalent to the tesamorelin VAT-reduction program. We position sermorelin as the alternative where (a) the patient cannot access tesamorelin through the partner pharmacy, (b) cost is a constraint, or (c) the patient prefers a shorter-acting GHRH analog. For a patient whose primary endpoint is visceral fat or muscle quality, tesamorelin is the cleaner first-line choice.
Where ipamorelin sits
Ipamorelin is a selective GH secretagogue — pentapeptide, ghrelin-receptor agonist — distinct in mechanism from a GHRH analog. The original pharmacology (Raun, 1998) showed selective GH release without cortisol, prolactin, or ACTH elevation. Ipamorelin returned to legal Category 1 compounding status in April 2026 and is on the July 23 PCAC docket separately. We add ipamorelin to a tesamorelin or sermorelin regimen for selected patients where pulsatile GH amplitude (sleep architecture, recovery) is the indication, contingent on the 503A partner pharmacy formulary. We re-check formulary availability before each new prescription rather than assuming it.
Why CJC-1295 is not on the menu
CJC-1295 (mod GRF 1-29, with or without DAC) is a synthetic GHRH analog that produces a sustained GH/IGF-1 elevation. In our verification work in May 2026, we confirmed that CJC-1295 is not currently legal for human compounding under the 503A framework and is not on the July 23–24 PCAC docket. The pathway to lawful prescribing would require a separate bulk-substance nomination, PCAC review, and final FDA rulemaking — a 1+ year process. Until that happens, prescribing CJC-1295 means sourcing from grey-market or overseas channels with no certificate of analysis, no stability data, and no patient-specific compounding pharmacy in the loop. That is not a tradeoff we are willing to make.
The clinical compromise is minimal. Tesamorelin produces a durable IGF-1 elevation at standard dosing without requiring the DAC modification CJC-1295 uses to extend half-life. The body-composition and muscle endpoints we care about are present in the tesamorelin literature and absent from the CJC-1295 literature.
The GH-axis menu, at a glance
| Peptide | Regulatory status (May 2026) | Position at Limitless |
|---|---|---|
| Tesamorelin | FDA-approved | Lead GH-axis recommendation. First line for VAT, muscle quality, body composition. |
| Sermorelin | Legal under 503A compounding | Alternative where tesamorelin is not indicated, accessible, or cost-appropriate. |
| Ipamorelin | Legal under 503A; on July 23 PCAC docket | Conditional add for pulsatile GH amplitude indications. Confirm partner pharmacy formulary before each prescription. |
| CJC-1295 (no DAC) | Not currently legal for 503A human compounding | Not on the menu. Re-evaluation requires a separate PCAC review and final rulemaking. |
| HGH (somatropin) | FDA-approved (specific indications) | Not on the menu for non-deficient patients. See why we do not prescribe HGH for performance. |
How we prescribe
Tesamorelin first. Sermorelin alternative. Ipamorelin conditional. CJC-1295 not on the menu.
Indication: adult patients with documented visceral adiposity, low muscle quality on imaging or assessment, or a body-composition endpoint that has plateaued on training and nutrition alone. Baseline IGF-1, A1c, fasting glucose, comprehensive metabolic panel.
Dosing: tesamorelin 2 mg SubQ daily, evening administration to align with endogenous GH pulse. 12-week cycles with reassessment. IGF-1 re-check at 12 weeks; titrate or pause if IGF-1 exceeds the age-adjusted upper reference range.
Adjuncts: ipamorelin 200–300 mcg SubQ at bedtime, 3–5 nights weekly, where pulsatile amplitude is the indication (sleep architecture, recovery), contingent on partner pharmacy formulary. Sermorelin 100–300 mcg SubQ at bedtime as alternative where indicated.
Foundations first. The GH axis is layered on top of optimized sleep, training, nutrition, and any indicated hormone optimization. Patients who are not adherent on the foundations do not get peptide adjuncts.
What we tell every patient
- Tesamorelin is FDA-approved for one specific indication; the body-composition and muscle effects we are targeting are off-label uses with strong supporting literature but outside the original label.
- The IGF-1 monitoring is not optional. We pause or titrate if IGF-1 climbs above the age-adjusted reference range.
- The peptide does not replace training, nutrition, or sleep. It compounds them.
- The regulatory situation has moved twice in 24 months. We will email patients within 30 days of any FDA action that changes the prescribing posture.
- CJC-1295, if encountered in marketing materials or another clinic's recommendation, is not currently legal for human compounding under 503A. That is a fact, not an opinion.
What updates this article
This article will update after the July 23, 2026 PCAC vote on ipamorelin (and the four Day-1 peptides on the docket), after the NCT06554717 exercise-adjunct trial reports, after any FDA final rule that changes the legal status of CJC-1295, and whenever a major peer-reviewed paper materially changes the body-composition or muscle evidence for tesamorelin or sermorelin.
The standing posture in the box above is what governs every new Limitless prescription as of 2026-05-15. It will be re-evaluated at the next material data point.